Myricx Bio is a private biotechnology company focused on the discovery and development of therapeutics for the treatment of patients with cancer. It has pioneered the development of a novel class of payloads for antibody-drug conjugates based on inhibition of N-myristoyltransferase.
Investment Rounds
Capital activity and funding progression
| Amount | Valuation | Date | Round | |
|---|---|---|---|---|
| $1.5 B | — | Jul, 2026 | acquisition | View |
Industries
Frequently Asked Questions
Where is Myricx Bio located?
Myricx Bio is located in London, United Kingdom.
What industries does Myricx Bio operate in?
Myricx Bio operates in the following industries: biotechnology, oncology, antibody-drug conjugates.
When was Myricx Bio founded?
Myricx Bio was founded on 2026-07-06.
How much total funding has Myricx Bio raised?
Myricx Bio has raised a total of $1,500,000,000.
Who are the investors in Myricx Bio?
The investors in Myricx Bio are: Novartis.
What is Myricx Bio?
Myricx Bio is a UK-based biotechnology company that specializes in discovering and developing a novel class of payloads for antibody-drug conjugates (ADCs) to treat various types of cancer.
What is the primary therapeutic focus of Myricx Bio?
The company focuses on inhibiting N-myristoyltransferases (NMT), an enzyme essential for the survival and growth of cancer cells, to create differentiated and effective cancer treatments.
Has Myricx Bio been acquired by another company?
Yes, in July 2026, it was announced that Novartis reached an agreement to acquire Myricx Bio in a transaction valued at up to 1.5 billion dollars.
What are the lead assets currently in the Myricx Bio pipeline?
Myricx Bio is developing lead assets that target B7-H3 and HER2, which are clinically validated cancer-associated antigens.